Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03655015 · ClinicalTrials.gov registry record
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
A clinical trial of Lung Neoplasm, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT03655015: Recruiting study of Lung Neoplasm, sponsored by The University of Texas Health Science Center at San Antonio.
NCT03655015 is a study of Lung Neoplasm that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 150 participants, below the 537-participant average among 8 other Lung Neoplasm trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03655015, a study of Lung Neoplasm, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Create a living biobank of PDOs from Stage I-III lung cancer patients.
Primary Outcome
Establishment of a living biobank of PDOs and the potential of PDOs to repeat their process outside a living organism
Conditions Studied
Interventions
- PROCEDURE Lung Tumor Resection
Study Locations (1)
Texas
- UT Health San Antonio, M.D. Anderson Cancer Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-10-16 |
| Est. Completion | 2029-12 |
What NCT03655015 shows while recruiting
NCT03655015 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 537-participant average among 8 other Lung Neoplasm trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Lung Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Lung Tumor Resection is the first listed.
NCT03655015 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03655015 about?
NCT03655015 is a clinical study titled "Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer". Create a living biobank of PDOs from Stage I-III lung cancer patients.
What is the current status of trial NCT03655015?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2018-10-16. Estimated completion is 2029-12.
What conditions does trial NCT03655015 study?
This clinical trial studies the following conditions: Lung Neoplasm.
What interventions are being tested in trial NCT03655015?
The interventions under investigation include: Lung Tumor Resection (PROCEDURE).
Who is sponsoring clinical trial NCT03655015?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03655015 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03655015's enrollment target sits among peer trials
150 6th of 8 higher than 3 of 8 other Lung Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
RECRUITING · NA
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
RECRUITING · Phase 2
-
Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules
ACTIVE NOT RECRUITING · NA
-
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
ACTIVE NOT RECRUITING · NA
-
False/Negative Rate of Lung Percutaneous Needle Biopsy
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI